Loading
Alterome Therapeutics makes tablets designed to switch off one specific faulty version of a cancer-driving protein, so that healthy cells are spared. Its two medicines, for cancers driven by mutant AKT1 or mutant KRAS, are in early trials.
Alterome Therapeutics, Inc. is a clinical-stage precision oncology company at 13480 Evening Creek Drive North, San Diego, California, developing internally discovered small molecules that bind specific mutant forms of cancer drivers. Tanerasertib (ALTA2618) is designed to inhibit the AKT1 E17K mutant and is in the phase 1/1b AKTive-001 study (NCT06533059) in AKT1 E17K-mutant advanced solid tumours, including breast and endometrial cancer; the company announced the first patient dosed on 30 October 2024. ALTA3263, which the company calls a pan-KRAS dual ON/OFF inhibitor, entered a phase 1/1b study (NCT06835569) in KRAS-mutant pancreatic, lung and colorectal cancers, with first dosing announced on 10 March 2025, alone and with cetuximab; first clinical data were due as a late-breaking presentation at the EORTC-NCI-AACR symposium in October 2026. The company launched in January 2022 with a USD 64 million Series A, extended it to nearly USD 100 million in November 2022, and raised a USD 132 million Series B led by Goldman Sachs Alternatives in April 2024. Its first registered cancer trial, NCT06533059, was posted on ClinicalTrials.gov in August 2024.
| Round | Year | Amount | Source |
|---|---|---|---|
| Series B · Led by Goldman Sachs Alternatives. | 2024 | $132M | alterome.com |
| Series A · Launch round; the company reported in November 2022 that it had extended the Series A to nearly USD 100 million. | 2022 | $64M | alterome.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Shares OrbiMed, KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma.
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma, Colorectal cancer.
Shares KRAS & RAS inhibitors, KRAS, Endometrial cancer, Pancreatic ductal adenocarcinoma.
Shares PI3K, AKT and mTOR inhibitors, Endometrial cancer, Breast cancer (all types), Colorectal cancer.
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma, Colorectal cancer.
Shares KRAS & RAS inhibitors, KRAS, Breast cancer (all types), Pancreatic ductal adenocarcinoma.
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma, Colorectal cancer.
Shares KRAS & RAS inhibitors, KRAS, Colorectal cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/